Contribution of Jim Tananbaum in Healthcare Sector

Chief Executive officer of Foresite Capital Jim Tananbaum and managing director of the firm, through the company, announced on Dr. Molly He as a venture partner. Dr. He is a former senior director at Illumina. She has experience of 15 years in Pharmaceuticals and genomic research and development. Jim Tananbaum recognizes Dr. He as one of the top respected scientific researchers in the filled with next-generation sequencing. She will be a priceless resource to Foresite Capital because of her broad knowledge in leadership skills and genomics and drug development.

At scientific research, Dr. He led the company into global reagent innovation and improvements when she was the director. She earned her Bachelor’s degree in biochemistry from Nankai University and Ph.D. in protein biophysics from the University of California, Los Angeles. Foresite Capital is reputed among the top companies in innovative and exciting healthcare. It aids emerging healthcare leaders with capital in both public and private sectors.

Tananbaum is the founder and Chief Executive officer of the Foresite Capital. With over 25 years of experience, Jim has invested and built various healthcare companies. Before founding Foresite Capital, he was a co-founder of other two best biopharmaceutical companies and health care investment practices. He founded GelTex Pharmaceuticals (NASDAQ: GENZ) Theravance, Inc. and a founding Partner of Prospect Venture Partners II and III. He was also a partner at Sierra Ventures. Jim Tananbaum has held various investments including Amira Pharmaceuticals, Amerigroup, Jazz Pharmaceuticals, and Healtheon. Jim Tananbaum has led an investment in about 21 healthcare companies successfully. He has held management positions at GeiTex Pharmaceuticals and Theravance.

Jim Tananbaum is an alumnus of Yale University where he earned a BS, and a B.S.E.E. Jim has M.D. from Harvard Medical School, MBA from Havard Business School. Dr. Tananbaum has served on the advisory board’s committees and visiting committees to the Harvard-MIT HST Program. He has also served on the advisory board and visiting committee of Yale School of Engineering. He is a renowned person in the area of health care innovation, investment, and development, and has extensive knowledge. Read more about Jim on


Categories: Investor